NDAORALTABLET, CHEWABLE
Approved
Oct 1980
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
AMOXIL (amoxicillin) by Pfizer is drug. Approved for helicobacter pylori infection, pneumonia, sinusitis and 10 more indications. First approved in 1980.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AMOXIL is an oral penicillin-based beta-lactam antibiotic used to treat a broad spectrum of bacterial infections including respiratory tract infections, urinary tract infections, skin infections, and Helicobacter pylori. It works by inhibiting bacterial cell wall biosynthesis, resulting in bactericidal activity against susceptible organisms during active multiplication. The drug is rapidly absorbed orally with peak blood levels achieved within 1-2 hours.
LOE Approaching
As LOE approaches, AMOXIL commercial teams are transitioning from growth to defensive strategies; brand team size likely stable or contracting as generics proliferate.
Mechanism of Action
drug. [see Microbiology (12.4)]. 12.3 Pharmacokinetics Absorption: Amoxicillin is stable in the presence of gastric acid and is rapidly absorbed after oral administration. The effect of food on the absorption of Amoxicillin from the tablets and suspension of Amoxicillin has been partially…
Worked on AMOXIL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.